[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622030":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":46,"collaborators":20,"id":48,"slug":20,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":20,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":20,"enrollmentInfo":56,"targetDuration":20,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Taichung Veterans General Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental Group","EXPERIMENTAL","Participants in this single experimental arm will receive three sessions of ultrasound-guided dextrose injections (e.g., 5% or 15% Dextrose) targeting symptomatic myofascial and interfascial planes of the ipsilateral chest wall and axilla, such as the pectoralis major-minor interface or axillary fascia. Injections are administered at 4-week intervals (at Baseline, Week 4, and Week 8). Throughout the 6-month study period, all participants continue their standardized rehabilitation program, which includes range-of-motion exercises, stretching of the chest wall and axillary musculature, and progressive strengthening.",[13],"Procedure: ultrasound guided dextrose prolotherapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"PROCEDURE","ultrasound guided dextrose prolotherapy","Participants receive three sessions of ultrasound-guided 5% dextrose injections into symptomatic myofascial and interfascial planes of the ipsilateral chest wall and axillary region. The technique involves identifying areas of soft-tissue thickening or restricted fascial glide under high-frequency ultrasound. Injection targets are individualized to each patient's specific site of restriction (e.g., clavipectoral fascia, pectoralis major-minor interface, or axillary fascia). Sessions are administered at 4-week intervals (at weeks 0, 4, and 8).",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Yuchun Lee, M.D.","PRINCIPAL_INVESTIGATOR",[26],{"name":23,"role":27,"phone":28,"phoneExt":29,"email":30},"CONTACT","886423592525","3507","lyczoj@vghtc.gov.tw",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":36,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Taichung Veterans Genetal Hospital","RECRUITING","Taichung","Taiwan","407",{"type":39,"coordinates":40},"Point",[41,42],120.6839,24.1469,{"lat":42,"lon":41},[45],{"name":23,"role":27,"phone":28,"phoneExt":29,"email":30},{"type":47,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100622030",false,"NCT07378319","Dextrose Hydrodissection for Post-Breast Cancer Chest Wall and Axillary Tightness.","Effectiveness of Ultrasound-Guided Dextrose Prolotherapy for Persistent Chest Wall and Axillary Symptoms in Breast Cancer Survivors: A Prospective Case Series.","Inclusion Criteria:\n\n* History of breast cancer surgery (mastectomy or breast-conserving surgery), with or without axillary lymph node dissection\n* Persistent ipsilateral chest wall and\u002For axillary pain, tightness, or movement restriction lasting ≥ 3 months after surgery;\n* Clinically significant baseline symptom severity, defined as Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH) questionnaire ≥ 25 and\u002For pain intensity ≥ 5\u002F10 on the Numeric Rating Scale (NRS);\n* Completion of 12 weeks of standard physical therapy with no significant improvement, defined as a change in QuickDASH score from baseline to completion of therapy below the minimal clinically important difference (MCID; \\\u003C15 points ) and\u002For pain improvement \\\u003C 2 points on the NRS .\n* Age ≥ 18 years;\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Evidence of local cancer recurrence or metastatic disease;\n* Active lymphedema requiring ongoing decongestive therapy at the time of enrollment;\n* Shoulder pathology, including intra-articular or peri-articular conditions (e.g., adhesive capsulitis with marked capsular restriction, or acute rotator cuff tear,) judged by clinical assessment to be the dominant cause of symptoms.\n* Active infection, skin lesion, or unhealed surgical wound at the intended injection site;\n* Known bleeding disorders or anticoagulant use contraindicating injection;\n* Known allergy to dextrose or any components of the injection protocol;\n* Pregnancy or other medical conditions precluding participation.","FEMALE","18 Years",{"count":57,"type":58},15,"ESTIMATED","INTERVENTIONAL",[61],"NA","The goal of this clinical trial (prospective case series) is to evaluate the feasibility, safety, and preliminary clinical outcomes of ultrasound-guided dextrose prolotherapy in female breast cancer survivors with persistent ipsilateral chest wall and axillary pain and tightness who have plateaued with standard physical therapy.\n\nThe main questions it aims to answer are:\n\nDoes ultrasound-guided dextrose prolotherapy significantly improve upper extremity functional limitation (measured by the QuickDASH questionnaire)?\n\nWhat are the effects of this intervention on pain intensity (NRS), active shoulder range of motion (AROM), and anterior chest wall soft-tissue tightness (pectoralis minor muscle length)?\n\nParticipants will:\n\nUndergo a comprehensive baseline physical examination and ultrasound assessment of the symptomatic chest wall and axilla.\n\nReceive three sessions of ultrasound-guided 5% dextrose injections into targeted soft-tissue planes at 4-week intervals.\n\nContinue their designated standard rehabilitation program, including range-of-motion and stretching exercises.\n\nAttend follow-up assessments at 4-week intervals during the treatment phase, with long-term follow-up at 3 and 6 months after the final injection to evaluate the durability of the response.",[64],"Breast Cancer Females",[66,67],"breast cancer","dextrose injection","2026-03-17",{"date":70,"type":71},"2026-03-20","ACTUAL",{"date":73,"type":71},"2025-01-11",{"date":75,"type":58},"2026-06-28",{"name":5,"class":6},1]